Elevated pressures in the heart can represent a severe medical condition known as pulmonary hypertension. This can result in chronic right heart failure. An abnormal increase in this pressure during exercise may be represent an early stage of vascular lung disease. This study will investigate the prognostic implications of the measured pressures obtained during exercise while undergoing a right heart catheterization procedure based on a large scale multi-center approach by using retrospective and prospective analysis of hemodynamic data.
The purpose of this study is to find out if levosimendan is safe and effective in improving symptoms and outcomes for patients with PH-HFpEF.
This study compares an active drug to a placebo. The participant will receive either the active drug, levosimendan, or a placebo via a 24 hour infusion. The study will take place over 6 weeks.
The purpose of this study is to find out if levosimendan is safe and effective in improving symptoms and outcomes for patients with PH-HFpEF who have previously participated in the TNX-LVO-04 study. All patients who are enrolled in this study will receive levosimendan weekly through a 24 hour infusion at their home. Office visits will occur at weeks 3, 6, 12, 24, 48, and final visit.
This study will involve subjects undergoing clinically indicated Right heart catheterization for either idiopathic pulmonary arterial hypertension (IPAH) or heart failure with preserved ejection fraction (HFpEF). The catheter tip utilized in the procedure, which would otherwise be discarded, will be collected and tested. A test performed on the cells adhered to the end of the catheters has been developed which we believe can aid in the differentiation of patients diagnosed with IPAH vs. HFpEF.
Patients with systemic sclerosis (SSc) related pulmonary arterial hypertension (SScPAH) have a worse prognosis than those with idiopathic PAH. We have recently discovered that heart cells in SScPAH do not contract or squeeze as well as in other forms of pulmonary hypertension. However, the mechanism leading to this dysfunction is not understood. To better study this and in hopes of developing a future therapy, we plan to collect tissue samples via a heart biopsy at the time of a clinically indicated heart catheterization.